Go Pro
→ DOJ Admits It In Court—Your Cash Can Be Seized Without Warning (From Priority Gold) (Ad)tc pixel Free OSUR Stock Alerts

OraSure Technologies (OSUR) Competitors

OraSure Technologies logo
$4.12 -0.04 (-0.84%)
As of 02:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

OSUR vs. CERS, UTMD, ANIK, WST, and COO

Should you buy OraSure Technologies stock or one of its competitors? MarketBeat compares OraSure Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with OraSure Technologies include Cerus (CERS), Utah Medical Products (UTMD), Anika Therapeutics (ANIK), West Pharmaceutical Services (WST), and Cooper Companies (COO).

How does OraSure Technologies compare to Cerus?

OraSure Technologies (NASDAQ:OSUR) and Cerus (NASDAQ:CERS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

OraSure Technologies has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Cerus has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market.

93.5% of OraSure Technologies shares are held by institutional investors. Comparatively, 78.4% of Cerus shares are held by institutional investors. 4.7% of OraSure Technologies shares are held by insiders. Comparatively, 5.3% of Cerus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cerus has a net margin of -3.06% compared to OraSure Technologies' net margin of -66.42%. Cerus' return on equity of -10.19% beat OraSure Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
OraSure Technologies-66.42% -18.57% -15.71%
Cerus -3.06%-10.19%-3.14%

OraSure Technologies currently has a consensus target price of $3.00, suggesting a potential downside of 27.10%. Cerus has a consensus target price of $4.00, suggesting a potential upside of 84.76%. Given Cerus' stronger consensus rating and higher probable upside, analysts clearly believe Cerus is more favorable than OraSure Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OraSure Technologies
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Cerus
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Cerus has higher revenue and earnings than OraSure Technologies. Cerus is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OraSure Technologies$115.02M2.46-$68.73M-$1.04N/A
Cerus$206.13M2.12-$15.63M-$0.03N/A

In the previous week, Cerus had 5 more articles in the media than OraSure Technologies. MarketBeat recorded 8 mentions for Cerus and 3 mentions for OraSure Technologies. Cerus' average media sentiment score of 0.48 beat OraSure Technologies' score of -0.25 indicating that Cerus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
OraSure Technologies
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cerus
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Cerus beats OraSure Technologies on 13 of the 16 factors compared between the two stocks.

How does OraSure Technologies compare to Utah Medical Products?

OraSure Technologies (NASDAQ:OSUR) and Utah Medical Products (NASDAQ:UTMD) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

OraSure Technologies has a beta of 1, indicating that its share price has a similar volatility profile to the broader market.Comparatively, Utah Medical Products has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

Utah Medical Products has lower revenue, but higher earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than Utah Medical Products, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OraSure Technologies$115.02M2.46-$68.73M-$1.04N/A
Utah Medical Products$38.52M5.98$11.29M$3.2822.08

OraSure Technologies presently has a consensus target price of $3.00, indicating a potential downside of 27.10%. Given OraSure Technologies' higher possible upside, research analysts plainly believe OraSure Technologies is more favorable than Utah Medical Products.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OraSure Technologies
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Utah Medical Products
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Utah Medical Products has a net margin of 29.04% compared to OraSure Technologies' net margin of -66.42%. Utah Medical Products' return on equity of 8.79% beat OraSure Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
OraSure Technologies-66.42% -18.57% -15.71%
Utah Medical Products 29.04%8.79%8.53%

In the previous week, OraSure Technologies had 2 more articles in the media than Utah Medical Products. MarketBeat recorded 3 mentions for OraSure Technologies and 1 mentions for Utah Medical Products. Utah Medical Products' average media sentiment score of -0.13 beat OraSure Technologies' score of -0.25 indicating that Utah Medical Products is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
OraSure Technologies
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Utah Medical Products
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

93.5% of OraSure Technologies shares are owned by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are owned by institutional investors. 4.7% of OraSure Technologies shares are owned by company insiders. Comparatively, 8.0% of Utah Medical Products shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Utah Medical Products beats OraSure Technologies on 10 of the 15 factors compared between the two stocks.

How does OraSure Technologies compare to Anika Therapeutics?

Anika Therapeutics (NASDAQ:ANIK) and OraSure Technologies (NASDAQ:OSUR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

91.5% of Anika Therapeutics shares are owned by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are owned by institutional investors. 12.1% of Anika Therapeutics shares are owned by insiders. Comparatively, 4.7% of OraSure Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Anika Therapeutics has higher revenue and earnings than OraSure Technologies. Anika Therapeutics is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anika Therapeutics$120.65M2.15-$10.88M-$0.27N/A
OraSure Technologies$115.02M2.46-$68.73M-$1.04N/A

Anika Therapeutics has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market. Comparatively, OraSure Technologies has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

Anika Therapeutics has a net margin of -3.14% compared to OraSure Technologies' net margin of -66.42%. Anika Therapeutics' return on equity of 0.20% beat OraSure Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Anika Therapeutics-3.14% 0.20% 0.15%
OraSure Technologies -66.42%-18.57%-15.71%

In the previous week, Anika Therapeutics had 13 more articles in the media than OraSure Technologies. MarketBeat recorded 16 mentions for Anika Therapeutics and 3 mentions for OraSure Technologies. Anika Therapeutics' average media sentiment score of 0.56 beat OraSure Technologies' score of -0.25 indicating that Anika Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Anika Therapeutics
4 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
OraSure Technologies
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Anika Therapeutics presently has a consensus target price of $21.00, indicating a potential upside of 8.47%. OraSure Technologies has a consensus target price of $3.00, indicating a potential downside of 27.10%. Given Anika Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Anika Therapeutics is more favorable than OraSure Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anika Therapeutics
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
OraSure Technologies
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Summary

Anika Therapeutics beats OraSure Technologies on 12 of the 16 factors compared between the two stocks.

How does OraSure Technologies compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and OraSure Technologies (NASDAQ:OSUR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

93.9% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are held by institutional investors. 0.6% of West Pharmaceutical Services shares are held by company insiders. Comparatively, 4.7% of OraSure Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

West Pharmaceutical Services has higher revenue and earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$3.07B7.96$493.70M$7.8144.49
OraSure Technologies$115.02M2.46-$68.73M-$1.04N/A

West Pharmaceutical Services has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, OraSure Technologies has a beta of 1, indicating that its stock price has a similar volatility profile to the broader market.

West Pharmaceutical Services has a net margin of 16.98% compared to OraSure Technologies' net margin of -66.42%. West Pharmaceutical Services' return on equity of 20.11% beat OraSure Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
West Pharmaceutical Services16.98% 20.11% 14.83%
OraSure Technologies -66.42%-18.57%-15.71%

In the previous week, West Pharmaceutical Services had 8 more articles in the media than OraSure Technologies. MarketBeat recorded 11 mentions for West Pharmaceutical Services and 3 mentions for OraSure Technologies. West Pharmaceutical Services' average media sentiment score of 1.63 beat OraSure Technologies' score of -0.25 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
West Pharmaceutical Services
10 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
OraSure Technologies
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

West Pharmaceutical Services currently has a consensus price target of $368.08, suggesting a potential upside of 5.93%. OraSure Technologies has a consensus price target of $3.00, suggesting a potential downside of 27.10%. Given West Pharmaceutical Services' stronger consensus rating and higher possible upside, research analysts plainly believe West Pharmaceutical Services is more favorable than OraSure Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services
0 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
2 Strong Buy rating(s)
3.00
OraSure Technologies
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Summary

West Pharmaceutical Services beats OraSure Technologies on 16 of the 17 factors compared between the two stocks.

How does OraSure Technologies compare to Cooper Companies?

Cooper Companies (NASDAQ:COO) and OraSure Technologies (NASDAQ:OSUR) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

24.4% of Cooper Companies shares are held by institutional investors. Comparatively, 93.5% of OraSure Technologies shares are held by institutional investors. 2.1% of Cooper Companies shares are held by insiders. Comparatively, 4.7% of OraSure Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cooper Companies has higher revenue and earnings than OraSure Technologies. OraSure Technologies is trading at a lower price-to-earnings ratio than Cooper Companies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cooper Companies$4.09B3.54$374.90M$1.1863.01
OraSure Technologies$115.02M2.46-$68.73M-$1.04N/A

Cooper Companies has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, OraSure Technologies has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

Cooper Companies currently has a consensus target price of $81.36, suggesting a potential upside of 9.42%. OraSure Technologies has a consensus target price of $3.00, suggesting a potential downside of 27.10%. Given Cooper Companies' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cooper Companies is more favorable than OraSure Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cooper Companies
3 Sell rating(s)
6 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.35
OraSure Technologies
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Cooper Companies has a net margin of 5.57% compared to OraSure Technologies' net margin of -66.42%. Cooper Companies' return on equity of 10.88% beat OraSure Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Cooper Companies5.57% 10.88% 7.27%
OraSure Technologies -66.42%-18.57%-15.71%

In the previous week, Cooper Companies had 14 more articles in the media than OraSure Technologies. MarketBeat recorded 17 mentions for Cooper Companies and 3 mentions for OraSure Technologies. Cooper Companies' average media sentiment score of 0.91 beat OraSure Technologies' score of -0.25 indicating that Cooper Companies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cooper Companies
9 Very Positive mention(s)
4 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
OraSure Technologies
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Cooper Companies beats OraSure Technologies on 14 of the 17 factors compared between the two stocks.

Get OraSure Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for OSUR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OSUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OSUR vs. The Competition

Export
MetricOraSure TechnologiesHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$283.32M$5.70B$6.80B$13.01B
Dividend YieldN/A1.78%2.60%10.03%
P/E Ratio-3.9623.54279.9825.51
Price / Sales2.4659.23649.35116.02
Price / CashN/A32.5328.6434.82
Price / Book0.876.5011.156.35
Net Income-$68.73M$151.72M$3.48B$347.60M
7 Day Performance2.36%6.11%2.51%3.14%
1 Month Performance-5.40%0.89%-2.78%-2.08%
1 Year Performance31.89%9.82%64.32%21.27%

OraSure Technologies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OSUR
OraSure Technologies
1.1048 of 5 stars		$4.13
-0.8%		$3.00
-27.3%		+38.2%$283.73M$115.02MN/A840
CERS
Cerus
2.3746 of 5 stars		$2.92
-5.0%		$4.00
+37.2%		+69.3%$584.08M$206.13MN/A290
UTMD
Utah Medical Products
1.2983 of 5 stars		$70.99
+2.7%		N/A+32.4%$226.21M$36.11M21.66180
ANIK
Anika Therapeutics
1.9103 of 5 stars		$15.08
+0.4%		$17.00
+12.8%		+140.0%$201.13M$112.82MN/A300
WST
West Pharmaceutical Services
3.9943 of 5 stars		$332.84
+0.5%		$364.42
+9.5%		+45.4%$23.69B$3.33B42.9410,800

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:OSUR) was last updated on 8/4/2026 by MarketBeat.com Staff.
From Our Partners
[URGENT] Mode Mobile terms changing Aug 14
Mode Mobile has secured its Nasdaq ticker, $MODE, while still in the pre-IPO stage. More than 60,000 investors...
Mode Mobile | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Nvidia's CEO says this small device is critical for AI growth
A tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it esse...
Brownstone Research | Sponsoredtc pixel
1 Stock to Own by July 31st
A scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-k...
Chaikin Analytics | Sponsoredtc pixel
He bet half his $9 billion on ONE stock
One of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...
Stansberry Research | Sponsoredtc pixel
They Crashed the Dollar 40% Before. It's Happening Again.
In 1985, world powers deliberately drove the dollar lower in a coordinated deal that drained everyday savers. ...
Priority Gold | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel